Challenges for cancer patients returning home during SARS-COV-19 pandemic after medical tourism - a consensus report by the emirates oncology task force
Open Access
- 10 July 2020
- journal article
- review article
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-10
Abstract
Background: The COVID-19 pandemic has caused a global health crisis. Numerous cancer patients from non-Western countries, including the United Arab Emirates (UAE), seek cancer care outside their home countries and many are sponsored by their governments for treatment. Many patients interrupted their cancer treatment abruptly and so returned to their home countries with unique challenges. In this review we will discuss practical challenges and recommendations for all cancer patients returning to their home countries from treatment abroad. Method: Experts from medical, surgical and other cancer subspecialties in the UAE were invited to form a taskforce to address challenges and propose recommendations for patients returning home from abroad after medical tourism during the SARS-COV-19 Pandemic. Results: The taskforce which consisted of experts from medical oncology, hematology, surgical oncology, radiation oncology, pathology, radiology and palliative care summarized the current challenges and suggested a practical approaches to address these specific challenges to improve the returning cancer patients care. Lack of medical documentation, pathology specimens and radiology images are one of the major limitations on the continuation of the cancer care for returning patients. Difference in approaches and treatment recommendations between the existing treating oncologists abroad and receiving oncologists in the UAE regarding the optimal management which can be addressed by early and empathic communications with patients and by engaging the previous treating oncologists in treatment planning based on the available resources and expertise in the UAE. Interruption of curative radiotherapy (RT) schedules which can potentially increase risk of treatment failure has been a major challenge, RT dose-compensation calculation should be considered in these circumstances. Conclusion: The importance of a thorough clinical handover cannot be overstated and regulatory bodies are needed to prevent what can be considered unethical procedure towards returning cancer patients with lack of an effective handover. Clear communication is paramount to gain the trust of returning patients and their families. This pandemic may also serve as an opportunity to encourage patients to receive treatment locally in their home country. Future studies will be needed to address the steps to retain cancer patients in the UAE rather than seeking cancer treatment abroad.Keywords
Funding Information
- Khalifa Bin Zayed Al Nahyan Foundation – Abu Dhabi – United Arab Emirates
- Roche
This publication has 40 references indexed in Scilit:
- Interruptions of Head and Neck Radiotherapy Across Insured and Indigent Patient PopulationsJournal of Oncology Practice, 2017
- Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast CancerJAMA Oncology, 2016
- Time to Surgery and Breast Cancer Survival in the United StatesJAMA Oncology, 2016
- Treatment Interruption During Concurrent Chemoradiotherapy of Uterine Cervical Cancer; Analysis of Factors and OutcomesAsian Pacific Journal of Cancer Prevention, 2014
- The risk of venous thrombosis after air travel: contribution of clinical risk factorsBritish Journal of Haematology, 2014
- Contemporary medical tourism: Conceptualisation, culture and commodificationTourism Management, 2013
- Health and health systems performance in the United Arab Emirates.2013
- Compensability index for compensation radiotherapy after treatment interruptionsRadiation Oncology, 2012
- Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Partnerships in Oncology and Radiology: The Role of Radiology in the Detection, Staging, and Follow-up of Lung CancerThe Oncologist, 2006